Correction: Govaerts et al. Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective Study. Cancers 2025, 17, 2425

Key Points

• The central aim is to assess the incidence and clinical characteristics of pseudoprogression in patients with brain metastases undergoing immune-checkpoint inhibitor therapy.
• Conducted a retrospective analysis of patient records
• Analyzed clinical data and imaging for evidence of pseudoprogression
• Evaluated therapeutic responses post-immune-checkpoint inhibitor treatment
• Identified a significant rate of pseudoprogression among treated patients
• Noted variations in clinical features that may affect treatment decisions
• Demonstrated the importance of distinguishing pseudoprogression from true progression